Differentially expressed miRNAs are associated with prognosis in WM patients, and drugs used to treat WM modulate their expression level. (A) Significant differential distribution of each indicated miRNA among subgroups of WM patients with differential clinical-prognostic features (low risk versus intermediate/high risk). Mean values were compared using Mann-Whitney U rank sum test; bars indicate standard errors. P value for each miRNA is indicated. (B) BCWM1 cells were treated with either rituximab (R; 10 μg/mL; 2 hours), perifosine (P; 10 μM; 6 hours), or bortezomib (B; 10 nM; 6 hours), and miRNA analysis was performed on total RNA isolated from treated and untreated cells. Heat map was generated after supervised hierarchic cluster analysis and comparison among the 2 groups (treated vs untreated samples). Differential expression of miRNA is shown by the intensity of red (up-regulation) or blue (down-regulation).